Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142116 is registered in ClinicalTrials.gov with Steven P. Treon, MD, PhD as lead sponsor.

NCT NCT00142116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00142116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Lead sponsor
Steven P. Treon, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
February 29, 2008
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoplasmacytic lymphoma, waldenstrom's macroglobulinemia